What We Do

We discover and develop innovative drug products for treatment of cardiometabolic and other diseases. Using our expertise in amino-lipid chemistry, we transform approved drugs or previously studied, biologically active agents to make them better for patients.

Pipeline

» TP-113 for type 2 diabetes

» TP-252 for familial adenomatous polyposis

» TP-452 for hypercholesterolemia

» TP-8452 for mixed dyslipidemia

Learn more about our pipeline. »»

News

July 10, 2015
Final Preclinical Data on TP-113 Show Reduced Insulin Resistance Presented at ICCR

June 12, 2015
Thetis Pharmaceuticals to Present at the BIO International Convention on June 16, 2015

April 29, 2015
Thetis Pharmaceuticals Presents Preclinical Data on Novel Oral Agent for Type 2 Diabetes

March 4, 2015
Notice of Allowance on Composition of Matter Patent Expanding Type 2 Diabetes Portfolio